Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
暂无分享,去创建一个
M. Sordo | J. Brownstein | I. Kohane | J. Glaser | V. Gainer | S. Murphy | A. Goldfine | R. Grant | A. Dubey | D. Nathan | Judith Colecchi
[1] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[2] Sebastian Schneeweiss,et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.
[3] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[4] Robert T. Chen,et al. Active Surveillance of Vaccine Safety: A System to Detect Early Signs of Adverse Events , 2005, Epidemiology.
[5] Manfred Hauben,et al. Signal detection in pharmacovigilance: empirical evaluation of data mining tools , 2005, Pharmacoepidemiology and drug safety.
[6] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[7] J. Avorn. In defense of pharmacoepidemiology--embracing the yin and yang of drug research. , 2007, The New England journal of medicine.
[8] Yoon K Loke,et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. , 2007, JAMA.
[9] C. Koro,et al. Studies of diabetes, thiazolidinediones, and coronary heart disease , 2007, Pharmacoepidemiology and drug safety.
[10] Sanjay Kaul,et al. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death , 2007, Annals of Internal Medicine.
[11] Tara Gomes,et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. , 2007, JAMA.
[12] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[13] Alfonso T. Perez,et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes , 2007, Pharmacoepidemiology and drug safety.
[14] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[15] N. Marchionni,et al. Rosiglitazone and cardiovascular risk. , 2007, The New England journal of medicine.
[16] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[17] R. Misbin. Lessons From the Avandia Controversy , 2007, Diabetes Care.
[18] L. Kennedy. Rosiglitazone Evaluated for Cardiovascular Outcomes—An Interim Analysis , 2008 .
[19] J. Leahy. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death , 2008 .
[20] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[21] W. Winkelmayer,et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. , 2008, Archives of internal medicine.
[22] Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000–2007 , 2008, Pharmacoepidemiology and drug safety.
[23] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[24] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[25] R. Tannen,et al. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings , 2009, BMJ : British Medical Journal.
[26] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[27] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .